

IN THE UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF DELAWARE

ENDO PHARMACEUTICALS INC. and)	
MALLINCKRODT LLC,)	
)	
Plaintiffs,)	
)	
v.)	C.A. No. 14-1382 (RGA)
)	
AMNEAL PHARMACEUTICALS, LLC and)	
AMNEAL PHARMACEUTICALS OF NEW)	
YORK, LLC,)	
)	
Defendants.)	

**ENDO PHARMACEUTICAL INC.'S NOTICE OF CROSS-APPEAL TO
THE UNITED STATES COURT OF APPEALS FOR THE FEDERAL CIRCUIT**

Notice is hereby given that Plaintiff Endo Pharmaceuticals Inc. (“Endo”) cross-appeals in the above-named case to the United States Court of Appeals for the Federal Circuit from the October 7, 2016 Opinion (D.I. 155) and Judgment entered on October 21, 2016 (D.I. 157), insofar as that Judgment denies Endo’s requests for relief regarding U.S. Patent No. 8,808,737 (“the ‘737 Patent”), and from the Orders preceding that Judgment, including without limitation:

- 1) The February 5, 2016, Ordered Stipulation (D.I. 107) dismissing Endo’s claim for infringement of the ‘737 patent;
- 2) The February 5, 2016, Partial Judgment (D.I. 108) that the claims of the ‘737 patent are invalid under 35 U.S.C. § 101, and dismissing Endo’s claims against Amneal for infringement of the ‘737 patent;
- 3) Magistrate Judge Thyng’s September 23, 2015, Report and Recommendation in *Endo Pharmaceuticals Inc. et al. v. Actavis Inc.*, No. 14-1381-RGA (D. Del. 2014) (the “Actavis Action”) recommending that Endo’s claims against Actavis for infringement of the ‘737 patent

be dismissed on the grounds that the '737 patent is invalid under 35 U.S.C. § 101 (D.I. 51 in the Actavis Action);

4) This *Court's* November 17, 2015 Order Adopting Judge Thyng's Report and Recommendation over Endo's objections, and accordingly dismissing Endo's claims against Actavis for infringement of the '737 patent (D.I. 67 in the Actavis Action), which was adopted by stipulation in this case (D.I. 107); and

5) all *opinions*, orders, and rulings subsumed therein and made prior and after thereto resulting in final judgment adverse to Endo's requests for relief.

MORRIS, NICHOLS, ARSHT & TUNNELL LLP

OF COUNSEL:

/s/ Derek J. Fahnestock

Jonathan D. Loeb
DECHERT LLP
2440 West El Camino Real, Suite 700
Mountain View, CA 94040
(650) 813-4800

Jack B. Blumenfeld (#1014)
Derek J. Fahnestock (#4705)
Stephen J. Kraftschik (#5623)
1201 North Market Street
P.O. Box 1347
Wilmington, DE 19899
(302) 658-9200
jblumenfeld@mnat.com
dfahnestock@mnat.com
skraftschik@mnat.com

Martin J. Black
Sharon K. Gagliardi
Julie Latsko
Joseph Gribbin
DECHERT LLP
Cira Centre
2929 Arch Street
Philadelphia, PA 19104
(215) 994-4000

*Attorneys for Plaintiff Endo Pharmaceuticals
Inc.*

Robert D. Rhoad
Brian M. Goldberg
DECHERT LLP
902 Carnegie Center, Suite 500
Princeton, NJ 08540
(609) 955-3200

November 17, 2016
10576132

CERTIFICATE OF SERVICE

I hereby certify that on November 17, 2016, I electronically filed the foregoing with the Clerk of the Court using CM/ECF, which will send notification of such filing to all registered participants.

I further certify that I caused to be served copies of the foregoing document on November 17, 2016, upon the following in the manner indicated:

Mary B. Matterer
Richard K. Herrmann
MORRIS JAMES LLP
500 Delaware Avenue, Suite 1500
Wilmington, DE 19899-2306
*Attorneys for Defendants Amneal
Pharmaceuticals, LLC and Amneal
Pharmaceuticals of New York, LLC*

BY ELECTRONIC MAIL

Jake M. Holdreith
Jamie R. Kurtz
Kelsey J. Thorkelson
ROBINS KAPLAN LLP
800 LaSalle Avenue, Suite 2800
Minneapolis, MN 55402
*Attorneys for Defendants Amneal
Pharmaceuticals, LLC and Amneal
Pharmaceuticals of New York, LLC*

BY ELECTRONIC MAIL

Oren D. Langer
ROBINS KAPLAN LLP
601 Lexington Avenue, Suite 3400
New York, NY 10022
*Attorneys for Defendants Amneal
Pharmaceuticals, LLC and Amneal
Pharmaceuticals of New York, LLC*

BY ELECTRONIC MAIL

/s/ Derek J. Fahnestock

Derek J. Fahnestock (#4705)